SCH 51866 | 167298-74-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: SCH 51866
• 英文别名: Cyclopent(4,5)imidazo(2,1-b)purin-4(1H)-one, 5,6a,7,8,9,9a-hexahydro-5-methyl-2-((4-(trifluoromethyl)phenyl)methyl)-, (6aR,9aS)-rel-；(11R,15S)-8-methyl-4-[[4-(trifluoromethyl)phenyl]methyl]-1,3,5,8,10-pentazatetracyclo[7.6.0.02,6.011,15]pentadeca-2(6),3,9-trien-7-one
• CAS: 167298-74-0
• 化学式: C₁₉H₁₈F₃N₅O
• 分子量: 389.38
• InChiKey: JOSMPBVYYKRYLG-OLZOCXBDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  28
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  SCH 51866 在 sodium hydroxide 作用下， 以88%的产率得到5-((3aR,6aS)-2-Oxo-hexahydro-cyclopentaimidazol-1-yl)-2-(4-trifluoromethyl-benzyl)-3H-imidazole-4-carboxylic acid methylamide
  参考文献：
  名称：

  Guanine hydrolysis under basic conditions to substituted imidazoles

  摘要：

  First base induced opening of multicyclic guanines to isolable substituted imidazoles, and possible mechanism for this observation are described. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(00)00770-x
• 作为产物：
  描述：

  6-氨基-2-甲基硫代-3-甲基尿嘧啶 在 palladium on activated charcoal N-甲基吡咯烷酮 、 氯化亚砜 、 硫酸 、 氢气 、 硝酸 、 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 异丙醇 、 乙腈 为溶剂， 20.0 ℃ 、413.68 kPa 条件下， 生成 SCH 51866
  参考文献：
  名称：

  A novel synthesis of guanine PDE inhibitors via tricyclic imidazopyrimidines

  摘要：

  A new method for the preparation of developmental tetracyclic guanine PDE inhibitors via a common tricyclic pyrimidine intermediate is described. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(03)00383-6

文献信息

• ARGINASE INHIBITORS AND METHODS OF USE
  申请人：CHRISTIANSON DAVID W.

  公开号：US20100189644A1

  公开（公告）日：2010-07-29

  The present invention is directed to arginase inhibitor compounds of formula IA or formula IB: or a pharmaceutically acceptable salt thereof, compositions containing these compounds, and methods of their use for the treatment and diagnosis of conditions characterized by upregulation of arginase, abnormally high arginase activity, or by abnormally low nitric oxide synthase activity.

  本发明涉及化合物IA或化合物IB的抑制剂，或其药用盐，含有这些化合物的组合物，以及用于治疗和诊断由精氨酸酶上调、异常高的精氨酸酶活性或异常低的一氧化氮合酶活性所特征的疾病的方法。
• Arginase Inhibitors and Methods of Use Thereof
  申请人：Tomczuk Bruce Edward

  公开号：US20120171116A1

  公开（公告）日：2012-07-05

  The present invention includes arginase enzyme inhibitors, compositions comprising these arginase inhibitors, and methods of treating or diagnosing conditions characterized either by abnormally high arginase activity or abnormally low nitric oxide levels in a mammal, comprising administering compositions of the invention to the mammal.

  本发明包括精氨酸酶抑制剂，包括这些精氨酶抑制剂的组合物，以及治疗或诊断以哺乳动物体内精氨酶活性异常高或一氧化氮水平异常低为特征的疾病的方法，包括将本发明的组合物给哺乳动物进行治疗。
• Use of PDE V inhibitors for improved fecundity in mammals
  申请人：——

  公开号：US20030018037A1

  公开（公告）日：2003-01-23

  The invention relates to the use of a cyclic guanosine 3′, 5′-monophosphate phosphodiesterase type five (cGMP PDE V) inhibitor for increasing fecundity in a mammal by one or more of (a) promoting the growth of an oocyte, zygote, blastocyst, embryo and/or foetus, (b) increasing the rate or probability of survival of an embryo and/or foetus and (c) increasing the birth weight of a progeny, or for increasing milk productivity.

  该发明涉及使用环状鸟苷酸3'，5'-单磷酸磷酸二酯酶类型五（cGMP PDE V）抑制剂，通过促进卵母细胞、受精卵、囊胚、胚胎和/或胎儿的生长（a），增加胚胎和/或胎儿的存活率或概率（b），增加子代的出生体重，或增加产奶量来增加哺乳动物的繁殖力。
• Pharmaceutical
  申请人：——

  公开号：US20040185094A1

  公开（公告）日：2004-09-23

  A method of treating an individual is described. The method comprise delivering to the individual an agent that is capable of modulating an intermediate conductance calcium-activated potassium (IK Ca ) channel in the sexual genitalia of the individual; wherein the modulation of the IK Ca channel by the agent is capable of mediating a relaxation of corpus cavernosal smooth muscle tone. The agent may be admixed with a pharmaceutically acceptable carrier, diluent or exicipient.

  本文描述了一种治疗个体的方法。该方法包括向个体输送能够调节个体生殖器中间电导性钙激活钾离子通道（IKCa）的药物；其中，药物对IKCa通道的调节能够介导海绵体平滑肌张力的松弛。该药物可以与药学上可接受的载体、稀释剂或辅料混合。
• Arginase inhibitors and methods of use
  申请人：ASTRAZENECA AB

  公开号：US10118936B2

  公开（公告）日：2018-11-06

  The present invention is directed to arginase inhibitor compounds of formula IA or formula IB: or a pharmaceutically acceptable salt thereof, compositions containing these compounds, and methods of their use for the treatment and diagnosis of conditions characterized by upregulation of arginase, abnormally high arginase activity, or by abnormally low nitric oxide synthase activity.

  本发明涉及式 IA 或式 IB 的精氨酸酶抑制剂化合物： 或其药学上可接受的盐、含有这些化合物的组合物，以及它们用于治疗和诊断以精氨酸酶上调、精氨酸酶活性异常高或一氧化氮合酶活性异常低为特征的疾病的方法。